Top news of 2025: Drugmakers invest in US capacities, agree to lower Medicaid prices; Pfizer buys obesity-focused biotech Metsera

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Norvir

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

50 API Suppliers, 23 USDMF, 12 CEP/COS, 1 JDMF, 8 EU WC, 3 KDMF, 8 NDC API, 27 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

342 Drugs in Development

342 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

137 FDF Dossiers, 43 FDA Orange Book, 42 Europe, 7 Canada, 5 Australia, 25 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 100MG;25MG, TABLET;ORAL - 200MG;50MG, TABLET;ORAL - 100MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 3 Rochem International Inc, 1 SPI Pharma, 10 DKSH, 1 PMC Isochem, 1 Pharm-RX Chemical, 6 Boai NKY Pharmaceuticals Ltd, 3 Gangwal Healthcare, 8 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 5 Kirsch Pharma, 4 ACG Worldwide, 7 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 17 BASF, 2 Bioplus Life Sciences, 1 CD Formulation, 1 Clariant, 12 Corel Pharma Chem, 1 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 4 Ideal Cures, 11 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 4 Microlex e.U, 2 Nanjing Bold Chemical, 1 Nitika Pharmaceutical Specialities, 4 Novo Excipients, 2 Pharmatrans-Sanaq, 3 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 3 Roquette, 15 Seppic, 2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Sigachi Industries, 1 Symrise, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

46 Coating Systems & Additives, 34 Solubilizers, 30 Fillers, Diluents & Binders, 26 Parenteral, 20 Topical, 20 Film Formers & Plasticizers, 19 Controlled & Modified Release, 18 Thickeners and Stabilizers, 17 Emulsifying Agents, 13 Taste Masking, 12 Direct Compression, 12 Lubricants & Glidants, 11 Granulation, 10 API Stability Enhancers, 9 Empty Capsules, 8 Surfactant & Foaming Agents, 5 Rheology Modifiers, 5 Co-Processed Excipients, 5 Disintegrants & Superdisintegrants, 4 Coloring Agents, 4 Vegetarian Capsules, 2 Chewable & Orodispersible Aids

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 2 Stock Recap #PipelineProspector, 158 News #PharmaBuzz

GLOBAL SALES INFORMATION

11 US Medicaid Prescriptions, 10 Regulatory FDF Prices, 18 Annual Reports

MARKET PLACE

25 APIs, 9 FDF Dossiers

PATENTS & EXCLUSIVITIES

29 US Patents, 57 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 3 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
30/12/2025	Lupin Manufacturing Solutions	India	LUPIN MANUFACTURING SOLUTIONS LTD	37050	RITONAVIR USP	2022-04-14	Active	II	N/A
30/12/2025	Ajinomoto Company	Japan	AJINOMOTO CO INC	11677	A-84538.0 (RITONAVIR)	1995-09-25	Inactive	II	N/A

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Norvir

Norvir

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

50 API Suppliers

23 USDMF

12 CEP/COS

1 JDMF

8 EU WC

3 KDMF

8 NDC API

27 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

342 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

137 FDF Dossiers

43 FDA Orange Book

42 Europe

7 Canada

5 Australia

25 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 100MG;25MG

TABLET;ORAL - 200MG;50MG

TABLET;ORAL - 100MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Minakem

3 Rochem International Inc

1 SPI Pharma

10 DKSH

1 PMC Isochem

1 Pharm-RX Chemical

6 Boai NKY Pharmaceuticals Ltd

3 Gangwal Healthcare

8 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

5 Kirsch Pharma

4 ACG Worldwide

7 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

17 BASF

2 Bioplus Life Sciences

1 CD Formulation

1 Clariant

12 Corel Pharma Chem

1 Finar

13 Gangwal Chemicals

1 Huzhou Sunflower Pharmaceutical

4 Ideal Cures

11 Kerry

3 Kima Chemical

6 Lonza Capsugel

4 Microlex e.U

2 Nanjing Bold Chemical

1 Nitika Pharmaceutical Specialities

4 Novo Excipients

2 Pharmatrans-Sanaq

3 Pluviaendo

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

3 Roquette

15 Seppic

2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

2 Sigachi Industries

1 Symrise

TABLET;ORAL - 12.5MG;75MG;50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons